Nasopharyngeal CarcinomaSymptoms, Doctors, Treatments, Advances & More
Learn About Nasopharyngeal Carcinoma
- Nasopharyngeal carcinoma
- Nasopharyngeal Cancer
Melvin Chua practices in Singapore, Singapore. Mr. Chua is rated as an Elite expert by MediFind in the treatment of Nasopharyngeal Carcinoma. His top areas of expertise are Nasopharyngeal Carcinoma, Prostate Cancer, Mononucleosis, Prostatectomy, and Orchiectomy.
Melanoma & Skin Cancer Center
Dr. Sue Yom is an expert in the radiation treatment and management of head, neck and lung cancers. In her research, Yom studies chemoradiation (a combination of chemotherapy and radiation) for these cancers. She also investigates image-guided radiation therapy and ways to reduce toxic effects using focused radiation techniques, emerging biological agents and radiation protectants. Yom earned her medical and doctoral degrees at the University of Pennsylvania. She completed a residency in radiation oncology at the MD Anderson Cancer Center. Yom has received numerous awards recognizing her commitment to patient care and patient-oriented research. Dr. Yom is rated as an Elite provider by MediFind in the treatment of Nasopharyngeal Carcinoma. Her top areas of expertise are Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Merkel Cell Carcinoma, and Olfactory Neuroblastoma.
ASST Spedali Civili Di Brescia
Paolo Bossi practices in Brescia, Italy. Mr. Bossi is rated as an Elite expert by MediFind in the treatment of Nasopharyngeal Carcinoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma, Adenoid Cystic Carcinoma, Laryngectomy, and Endoscopy.
Summary: This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with mo...
Summary: This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1140 is a monoclonal antibo...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center